<DOC>
	<DOCNO>NCT01034969</DOCNO>
	<brief_summary>The Firazyr® Patient Registry prospective , observational study design document routine clinical outcome time patient treat Firazyr® country currently approve . The data collect used evaluate safety Firazyr® routine clinical practice data source post-marketing investigation .</brief_summary>
	<brief_title>Firazyr® Patient Registry Protocol ( Icatibant Outcome Survey - IOS )</brief_title>
	<detailed_description>The Firazyr® Patient Registry multicenter , prospective , observational study patient treat Firazyr® country currently approve . The entry patient Firazyr® Registry discretion physician patient pre-requisite prescribing Firazyr® .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<criteria>Each patient must meet follow criterion enrol registry . 1 . Diagnosis least 1 follow : HAE type I II HAE normal C1 inhibitor ACE I induce angioedema Non histaminergic idiopathic angioedema Acquired angioedema 2 . Signed date write informed consent patient , patient age &lt; 18 year ( per local regulation , &lt; 16 year United Kingdom [ UK ] ) , parent and/or patient 's legally authorize representative ( LAR ) , assent minor applicable 3 . At site participate drug registry aspect study , patient must take least 1 dose Firazyr ( icatibant ) . 1 . Patients enrol clinical trial product blind product investigation treatment HAE , ACE I induce angioedema , non histaminergic idiopathic angioedema , acquire angioedema . 2 . Patients enrol another Shiresponsored registry involve product treatment HAE , ACE I induce angioedema , non histaminergic idiopathic angioedema , acquire angioedema .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hereditary angioedema</keyword>
</DOC>